Research Professor School of Innovation and Entrepreneurship
Yiming Li, Research Professor of Biochemistry in School of Innovation and Entrepreneurship, Ph.D. of Zoology (Zhongshan University, 1988), Ph.D. of Biochemistry (Uppsala University, Sweden, 1997). He has many years of research experience in academic Institutes (Uppsala University, Karolinska Institute and Harvard University) and Industry (Human Genome Sciences, Inc., and AstraZeneca) in Europe and USA, working on protein separation and analysis method developments and their applications on biomedical research, protein drug development and recombinant protein production. He has published over 20 papers in the peer-reviewed journals, such as Nature, Cell, PNAS, Analytical Chemistry, Journal of Neuroscience, Journal of Biological Chemistry, Analytical Biochemistry, and Journal of Pharmaceutical Sciences.
Professor Yiming Li got his Bachelor, Master and Ph.D. in zoology in Zhongshan University (Guangzhou, China) in 1982, 1985 and 1988 respectively. From 1990 to 1998, he worked as a visiting scholar in Uppsala University and Karolinska Institute in Sweden, working on technology development and applications of separation techniques, especially HPLC. He developed an unconventional method for preparing various kinds of capillary HPLC columns. This progress was published in Nature and Analytical Biochemistry and was recognized as an important advancement in HPLC technology development. In addition to finishing his postdoctoral projects, Dr. Li accomplished the courses and thesis for Ph.D. and got his Ph.D. in Biochemistry in Uppsala University in 1997. He joined Professor Larry Benowitz’s group in Harvard Medical School in 1998 as a research fellow to study the mechanism of nerve regeneration. He discovered that mannose and glucose can stimulate axon regeneration in goldfish retinal ganglion cells, but only mannose can stimulate axon regeneration in rat retinal ganglion cells with the mechanism different from that for goldfish retinal ganglion cells (J. Neurosci., 2003, 23: 7830-7838). He elucidated the key role of MST3b protein kinase in nerve cell regeneration (Proc. Natl. Acad. Sci. USA, 2006, 103: 18320-18325). In Harvard Medical School, he also participated in a research project carried out by Professor Xi He's group to study the mechanism behand beta-catenin degradation. He made an important contribution to the elucidation of the key role of CKlα in beta-catenin degradation by purifying this protein kinase. This progress (Cell, 2002, 108: 837-847) was recognized as an important progress in tumor biology. After his postdoctoral research in Harvard Medical School, Dr. Li worked as a Scientist, Senior Scientist in Human Genome Sciences, Inc. (2002 -2009) and Scientist II in AstraZeneca (2009 -2016), engaged in protein drug development. He characterized the self-association of human interferon-α2b, PEGasys and Alb-interferon-α2b. This work provided the basis for evaluating the stability of these drug proteins and the potential risk of the self-association of these proteins in inducing immunogenicity in patients (J. Pharm. Sci., 2011, 101: 68–80). In 2016, he founded Biosolutions-Plus, Inc., working on the development of methanol-independent Pichia pastoris recombinant protein expression system for protein production. Dr. Li joined Southern University of Science and Technology as a Research Professor in 2018. He focuses his research on technology developments for recombinant protein production, protein purification and analysis, drug protein quality and stability analysis; research and development of biocatalysts for biodiesel production, drug and chemical intermediate synthesis; technology development for enzyme immobilization.
Ph.D. in Biochemistry: 1994.08 – 1997.11., Department of Biochemistry, Uppsala University, Uppsala, Sweden.
Ph.D, in Zoology: 1985.03. – 1988. 08., Department of Biology. Zhongshan University, Guangzhou, China.
Master of Science in Zoology: 1982.03. – 1985.02., Department of Biology, Zhongshan University, Guangzhou, China.
Bachelor of Science in Zoology: 1978.03. – 1982.01., Department of Biology, Zhongshan University, Guangzhou, China.
2018.10. – Present: Research Professor, Southern University of Science and Technology, Shenzhen, China.
2016.09. – 2018.09.: Chief Scientific Officer, Biosolutions-Plus, USA.
2009.09 – 2016.08.: Scientist II, Medimmune LLC. (AstraZeneca), USA.
2002.05 – 2009.08.: Scientist, Senior Scientist, Human Genome Sciences, Inc. USA.
1998.08 – 2002.04.: Postdoctoral Research Fellow, Harvard Medical School, USA.
1997.12. – 1998.07.: Postdoctoral Researcher, Uppsala University, Sweden.
1990.01, - 1994.07.: Postdoctoral Researcher, Uppsala University and Karolinska Institute, Sweden.
1988.09. – 1989.12.: Engineer, Shenzhen Science and Technology Development and Exchange Center.
Technology developments for recombinant protein production, protein purification and analysis, drug protein quality and stability analysis; research and development of biocatalysts for biodiesel production, drug and chemical intermediate synthesis; technology development for enzyme immobilization.